

Imipenem + cilastatin + relebactam

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

General description

INN

Imipenem + cilastatin + relebactam

ATC codes

[J01DH56](#)

Medicine type

Chemical agent

Antibiotic groups

[RESERVE](#)

EML status history

Application rejected in 2023 ([TRS 1049](#)) for [Carbapenem-resistant Pseudomonas aeruginosa](#)

Application rejected in 2023 ([TRS 1049](#)) for [Carbapenem resistant Enterobacterales](#)

Application rejected in 2023 ([TRS 1049](#)) for [Other specified other antibiotic resistant Enterobacterales](#)

Wikipedia

[Imipenem + cilastatin + relebactam](#)

DrugBank

[Imipenem](#),

[Cilastatin](#),

[Relebactam](#)

Recommendations

Section

Reserve group antibiotics

- Parenteral > General injections > IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection
- Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#) [Carbapenem resistant Enterobacterales](#) [Other specified other antibiotic resistant Enterobacterales](#)